Condition: Colorectal Cancer · Sponsor: Gruppo Oncologico del Nord-Ovest
The aim of this study is to evaluate the efficacy of the addition of Atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with pMMR and Immunoscore IC-high metastatic colorectal cancer in terms of Progression Free Survival (PFS).
This description comes directly from the study's public registry record.
Carlotta Antoniotti, MD, PhD · +39050992192 · carlotta.antoniotti@unipi.it
Laura Delliponti · +39050992192 · atezotribe2@gmail.com
Always discuss trial participation with your own doctor first.
| Fondazione Poliambulanza, Istituto Ospedaliero | Brescia, BS, Italy | Recruiting |
| Azienda Ospedaliero Universitaria Policlinico Rodolico - S. Marco | Catania, CT, Italy | Recruiting |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori | Meldola, FC, Italy | Recruiting |
| Fondazione Casa Sollievo della Sofferenza | San Giovanni Rotondo, FG, Italy | Recruiting |
| AOU Careggi | Florence, FI, Italy | Recruiting |
| Azienda Ospedaliera Card. G. Panico | Tricase, LE, Italy | Recruiting |
| Azienda USL Toscana Nord Ovest | Livorno, LI, Italy | Recruiting |
| Ospedale San Luca | Lucca, LU, Italy | Recruiting |
| Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milan, MI, Italy | Recruiting |
| Ospedale San Raffaele | Milan, MI, Italy | Recruiting |
| Fondazione IRCCS INT - Milano | Milan, MI, Italy | Recruiting |
| Azienda Ospedaliero Universitaria di Modena | Modena, MO, Italy | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06733038